Quince Therapeutics to Present at Citizens Life Sciences Conference

4/30/25 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $QNCX alert in real time by email

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time.

A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics, Inc. (NASDAQ:QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250430083242/en/

Media & Investor Contact:

Stacy Roughan

Quince Therapeutics, Inc.

Vice President, Corporate Communications & Investor Relations

[email protected]

Get the next $QNCX alert in real time by email

Date

Price Target

Rating

Analyst

8/5/2025

$9.00

Mkt Outperform

Citizens JMP

3/24/2025

$10.00

Outperform

Oppenheimer

Quince Therapeutics to Present at Citizens Life Sciences Conference

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$QNCX

Quince Therapeutics to Present at Citizens Life Sciences Conference

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$QNCX

$QNCX
Press Releases

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

$QNCX
Insider Trading

CBO, COO & CCO Hannah Brendan was granted 37,736 shares, increasing direct ownership by 13% to 334,276 units (SEC Form 4)

President Ryan Charles S. was granted 7,548 shares, increasing direct ownership by 6% to 130,009 units (SEC Form 4)

CEO and CMO Thye Dirk was granted 150,944 shares, increasing direct ownership by 18% to 994,885 units (SEC Form 4)

$QNCX
Analyst Ratings

Citizens JMP initiated coverage on Quince Therapeutics with a new price target

Oppenheimer initiated coverage on Quince Therapeutics with a new price target

$QNCX
Insider Purchases

CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

$QNCX
SEC Filings

SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.

SEC Form 10-Q filed by Quince Therapeutics Inc.

Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$QNCX
Leadership Updates

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

$QNCX
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

SEC Form SC 13D filed by Quince Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

$QNCX
Financials

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Quince Therapeutics to Present at Citizens Life Sciences Conference

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $QNCX

Quince Therapeutics to Present at Citizens Life Sciences Conference

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $QNCX

$QNCX Press Releases

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

$QNCX Insider Trading

CBO, COO & CCO Hannah Brendan was granted 37,736 shares, increasing direct ownership by 13% to 334,276 units (SEC Form 4)

President Ryan Charles S. was granted 7,548 shares, increasing direct ownership by 6% to 130,009 units (SEC Form 4)

CEO and CMO Thye Dirk was granted 150,944 shares, increasing direct ownership by 18% to 994,885 units (SEC Form 4)

$QNCX Analyst Ratings

Citizens JMP initiated coverage on Quince Therapeutics with a new price target

Oppenheimer initiated coverage on Quince Therapeutics with a new price target

$QNCX Insider Purchases

CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

$QNCX SEC Filings

SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.

SEC Form 10-Q filed by Quince Therapeutics Inc.

Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$QNCX Leadership Updates

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

$QNCX Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

SEC Form SC 13D filed by Quince Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

$QNCX Financials

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Recent Analyst Ratings for
$QNCX

Recent Analyst Ratings for
$QNCX

$QNCX
Press Releases

$QNCX
Insider Trading

$QNCX
Analyst Ratings

$QNCX
Insider Purchases

$QNCX
SEC Filings

$QNCX
Leadership Updates

$QNCX
Large Ownership Changes

$QNCX
Financials